Bull, Bear & Beyond – SynAct Pharma: executive interview

In this interview, we speak with SynAct Pharma CBO Mads Bjerregaard about the proposed co-development and commercial partnership with Hipolabor for resomelagon in dengue and other viral infections in Brazil, the world’s largest dengue market. He discusses why growing momentum from the RESOVIR collaboration and ongoing RESOVIR-2 Phase II study made this the right time to establish a commercial pathway in Brazil, and why SynAct opted for a differentiated 50:50 development-cost and profit-sharing model that aligns incentives while leveraging Hipolabor’s local regulatory and commercial capabilities. Mads also outlines how RESOVIR-2 could inform the path towards Phase III and regulatory discussions with the Brazilian regulatory authority ANVISA, and why being ready to capitalise on future dengue seasons could be important for efficient patient recruitment. Finally, he explains why the dengue deal represents a distinct partnering model and how SynAct has preserved full flexibility to pursue potentially more conventional global or regional partnerships for resomelagon in rheumatoid arthritis and other autoimmune diseases.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.